Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Distribution agreement for Genesis products

16 Jul 2009 07:00

RNS Number : 7478V
Omega Diagnostics Group PLC
16 July 2009
 



AIM: ODX

Omega Diagnostics Group PLC ('Omega')

UK Distribution agreement for Genesis products 

Omega, the AIM listed medical diagnostics company, announces that its UK-based subsidiary, Genesis Diagnostics Ltd ('Genesis') has signed an exclusive distribution agreement with Biohit Healthcare Ltd ('Biohit'), the UK-based subsidiary of Biohit Oyj, a Finnish public company which develops, manufactures and markets liquid handling products and diagnostic test systems for use in research, health care and industrial laboratories.

Biohit will take on the UK distribution and servicing of the Genesis product range using their UK-wide sales force and will offer complete coverage of the UK NHS hospital network. Both companies are committed to maintaining and improving upon the high level of customer service provided by Genesis. Biohit already services many current Genesis customers and the customer base is expected to expand as a result of this agreement.

Andrew Shepherd, Chief Executive of Omega, said, "The synergy between Genesis and Biohit is clear in that both companies service the same clinical laboratory market with complementary products. The UK market for clinical diagnostic products is highly competitive and we need to have a full scale sales force that can operate across the UK and increase our business base going forward. Using Biohit provides us with access to a much enlarged customer base and allows our resources to be focussed on other growth areas in the UK and beyond."

 

Richard Vaughton, Managing Director of Biohit commented, "The addition of Genesis products enhances the offering to our current customer base and helps focus our sales drive in the clinical laboratory market. We look forward to providing an excellent service to existing Genesis customers, many of whom we are familiar with, and to winning many new customers."

Further enquiries:

Omega Diagnostics Group PLC:

Tel: 01259 763 030

Andrew Shepherd, Chief Executive

Kieron Harbinson, Finance Director

www.omegadiagnostics.com

Cenkos Securities plc

Tel : 020 7397 8900

Nick Wells, Andy Roberts, Elizabeth Bowman

ebowman@cenkos.com

Walbrook PR Limited

Tel : 020 7933 8787

Paul McManus

Mob : 07980 541 893

paul.mcmanus@walbrookpr.com

Information on Biohit Oyj

Biohit Oyj, a Finnish Public company, develops, manufactures and markets liquid handling products and diagnostic test systems for use in research, health care and industrial laboratories.

Established in 1988, Biohit Oyj is headquartered in Finland. Biohit has subsidiaries in FranceGermany, the UKRussiaChinaJapan and the USA. Additionally, Biohit's products are sold by approximately 450 distributors in 70 countries. Biohit Oyj had net sales of 35.1M euros in 2008 and employed 370 personnel. 

Geographically sales are split as follows: Europe: 55.6%North & South America 18.1%Asia 11.5%Other Countries 14.8%

Biohit's shares (BIOBV) are quoted on NASDAQ OMX Helsinki. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRBLGDRBBBGGCU
Date   Source Headline
4th Jan 20224:36 pmRNSPrice Monitoring Extension
14th Dec 20217:00 amRNSConfirmation of detection of Omicron variant
10th Dec 20212:06 pmRNSSecond Price Monitoring Extn
10th Dec 20212:01 pmRNSPrice Monitoring Extension
10th Dec 20219:30 amRNSDHSC contract update
1st Dec 20214:40 pmRNSSecond Price Monitoring Extn
1st Dec 20214:35 pmRNSPrice Monitoring Extension
1st Dec 20212:05 pmRNSSecond Price Monitoring Extn
1st Dec 20212:00 pmRNSPrice Monitoring Extension
26th Nov 20212:06 pmRNSSecond Price Monitoring Extn
26th Nov 20212:00 pmRNSPrice Monitoring Extension
25th Nov 20219:06 amRNSSecond Price Monitoring Extn
25th Nov 20219:00 amRNSPrice Monitoring Extension
25th Nov 20217:00 amRNSHalf-year Report
5th Nov 20217:00 amRNSNotice of Results and Investor Presentation
3rd Nov 20217:00 amRNSUpdate on CTDA Regulations
1st Nov 20213:28 pmRNSExercise of Options and Total Voting Rights
1st Nov 20217:00 amRNSPartnership with DAM Health and initial LFT order
19th Oct 202112:00 pmRNSExercise of Options and Total Voting Rights
15th Sep 20213:26 pmRNSResult of AGM
15th Sep 20217:00 amRNSAGM Statement
30th Jul 202112:35 pmRNSPosting of Annual Report & Accounts &Notice of AGM
27th Jul 20217:00 amRNSAbC-19 monitors vaccine response to variants
13th Jul 20217:01 amRNSFinal Results
13th Jul 20217:00 amRNSDirectorate Change
9th Jul 20219:08 amRNSAbC-19 rapid antibody test performance evaluation
2nd Jul 20217:00 amRNSFDA submission for Emergency Use Authorization
16th Jun 20217:00 amRNSNotice of Results
15th Jun 202110:49 amRNSStatement re. Media Comment
10th Jun 20212:05 pmRNSSecond Price Monitoring Extn
10th Jun 20212:00 pmRNSPrice Monitoring Extension
8th Jun 20217:00 amRNSRegulatory progress for VISITECT® COVID-19 test
7th Jun 20217:00 amRNSProgress update
1st Jun 20217:00 amRNSPositive data for COVID-19 antigen test
6th May 20214:41 pmRNSSecond Price Monitoring Extn
6th May 20214:35 pmRNSPrice Monitoring Extension
5th May 20217:00 amRNSPositive data for Mologic COVID-19 antigen test
30th Apr 20211:30 pmRNSExercise of Options and Total Voting Rights
30th Apr 20217:00 amRNSLaunch of VISITECT® COVID-19 Antigen & Update
23rd Apr 202110:30 amRNSDirector/PDMR Shareholding and Total Voting Rights
19th Apr 20217:00 amRNSDirector/PDMR Shareholding
31st Mar 202112:31 pmRNSDirector/PDMR Shareholding and Total Voting Rights
26th Mar 20215:36 pmRNSExercise of Options and Total Voting Rights
26th Mar 20214:40 pmRNSSecond Price Monitoring Extn
26th Mar 20214:35 pmRNSPrice Monitoring Extension
22nd Mar 20217:00 amRNSCE-Mark: Mologic COVID19 lateral flow antigen test
19th Mar 20211:15 pmRNSExercise of Options and Total Voting Rights
15th Mar 20215:28 pmRNSStatement re. Government press release
15th Mar 20217:00 amRNSUK Public Sector Contract disclosure
8th Mar 20217:00 amRNSGrant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.